Matches in SemOpenAlex for { <https://semopenalex.org/work/W2539128838> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2539128838 endingPage "99" @default.
- W2539128838 startingPage "99" @default.
- W2539128838 abstract "Abstract The preceding trial HD9 had shown a significant superiority for escalated BEACOPP (EB) for failure-free survival (FFTF) and overall survival (OS) over COPP/ABVD or baseline BEACOPP (BB) (each 8 cycles). HD12 aimed to de-escalate chemotherapy by comparing 8 cycles EB with 4 cycles EB plus 4 cycles BB, with or without consolidatory 30 Gy radiation (RT) to initial bulky and residual disease. A total of 1661 patients aged 16–65 with HL in stage IIB (large mediastinal mass and/or E-lesions) or stage III-IV were randomised from 9/1999-1/2003 according to a factorial design between: 8EB + RT, 8EB no RT, 4EB+4BB + RT, 4EB+4BB no RT. A central diagnostic panel reviewed CT images after completion of chemotherapy independent of randomisation arm, and prescribed RT in selected cases. In the fifth analysis of HD12 (5/2006), 94% of all 1593 eligible randomised patients were evaluable, including 1498 for the chemotherapy comparison and 1449 for the radiotherapy comparison. Patient characteristics were very similar for all 4 arms. Radiation was given in arms with planned RT in 65%, in arms with no planned RT in 10%. 93% of all patients reached a complete remission, 2.2% suffered early progression, 4.6% relapsed and 8.2% died with a median folllow-up time of 48 months. Death due to acute toxicity was 3.2% (sepsis, cardiac, pulmonary, infection), with 21 such deaths in the 8EB arms and 27 in the 4EB+4BB arms. Secondary neoplasias were observed in 55 patients (3.7%): 14 AML/MDS, 12 NHL and 29 solid tumors/others. Four-year Kaplan-Meier estimates for arm pairs according to the factorial design were: 4 year rates, %(95% CI) 8EB vs. 4EB+4BB with RT vs. without RT FFTF 88(86–91) 86(83–89) 91(89–93) 88(86–91) OS 93(91–95) 91(89–93) No significant differences were observed when comparing treatments according to the sequential analysis plan (N.B. 10% received RT in arms ‘without RT’). The final analysis, scheduled when 80% of patients have 5 years follow-up, must be awaited before final conclusions can be drawn." @default.
- W2539128838 created "2016-10-28" @default.
- W2539128838 creator A5000334325 @default.
- W2539128838 creator A5003056562 @default.
- W2539128838 creator A5011847905 @default.
- W2539128838 creator A5025270469 @default.
- W2539128838 creator A5030433016 @default.
- W2539128838 creator A5033935778 @default.
- W2539128838 creator A5039994927 @default.
- W2539128838 creator A5057387418 @default.
- W2539128838 creator A5057543920 @default.
- W2539128838 creator A5066624700 @default.
- W2539128838 creator A5067574718 @default.
- W2539128838 creator A5071950409 @default.
- W2539128838 creator A5079589440 @default.
- W2539128838 creator A5087532681 @default.
- W2539128838 date "2006-11-16" @default.
- W2539128838 modified "2023-10-16" @default.
- W2539128838 title "HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany." @default.
- W2539128838 doi "https://doi.org/10.1182/blood.v108.11.99.99" @default.
- W2539128838 hasPublicationYear "2006" @default.
- W2539128838 type Work @default.
- W2539128838 sameAs 2539128838 @default.
- W2539128838 citedByCount "7" @default.
- W2539128838 countsByYear W25391288382012 @default.
- W2539128838 countsByYear W25391288382014 @default.
- W2539128838 crossrefType "journal-article" @default.
- W2539128838 hasAuthorship W2539128838A5000334325 @default.
- W2539128838 hasAuthorship W2539128838A5003056562 @default.
- W2539128838 hasAuthorship W2539128838A5011847905 @default.
- W2539128838 hasAuthorship W2539128838A5025270469 @default.
- W2539128838 hasAuthorship W2539128838A5030433016 @default.
- W2539128838 hasAuthorship W2539128838A5033935778 @default.
- W2539128838 hasAuthorship W2539128838A5039994927 @default.
- W2539128838 hasAuthorship W2539128838A5057387418 @default.
- W2539128838 hasAuthorship W2539128838A5057543920 @default.
- W2539128838 hasAuthorship W2539128838A5066624700 @default.
- W2539128838 hasAuthorship W2539128838A5067574718 @default.
- W2539128838 hasAuthorship W2539128838A5071950409 @default.
- W2539128838 hasAuthorship W2539128838A5079589440 @default.
- W2539128838 hasAuthorship W2539128838A5087532681 @default.
- W2539128838 hasConcept C126322002 @default.
- W2539128838 hasConcept C126894567 @default.
- W2539128838 hasConcept C141071460 @default.
- W2539128838 hasConcept C146357865 @default.
- W2539128838 hasConcept C151730666 @default.
- W2539128838 hasConcept C181199279 @default.
- W2539128838 hasConcept C185592680 @default.
- W2539128838 hasConcept C2776217839 @default.
- W2539128838 hasConcept C2776305933 @default.
- W2539128838 hasConcept C2776694085 @default.
- W2539128838 hasConcept C2776755627 @default.
- W2539128838 hasConcept C2779219270 @default.
- W2539128838 hasConcept C2779429289 @default.
- W2539128838 hasConcept C2779543040 @default.
- W2539128838 hasConcept C509974204 @default.
- W2539128838 hasConcept C55493867 @default.
- W2539128838 hasConcept C71924100 @default.
- W2539128838 hasConcept C86803240 @default.
- W2539128838 hasConceptScore W2539128838C126322002 @default.
- W2539128838 hasConceptScore W2539128838C126894567 @default.
- W2539128838 hasConceptScore W2539128838C141071460 @default.
- W2539128838 hasConceptScore W2539128838C146357865 @default.
- W2539128838 hasConceptScore W2539128838C151730666 @default.
- W2539128838 hasConceptScore W2539128838C181199279 @default.
- W2539128838 hasConceptScore W2539128838C185592680 @default.
- W2539128838 hasConceptScore W2539128838C2776217839 @default.
- W2539128838 hasConceptScore W2539128838C2776305933 @default.
- W2539128838 hasConceptScore W2539128838C2776694085 @default.
- W2539128838 hasConceptScore W2539128838C2776755627 @default.
- W2539128838 hasConceptScore W2539128838C2779219270 @default.
- W2539128838 hasConceptScore W2539128838C2779429289 @default.
- W2539128838 hasConceptScore W2539128838C2779543040 @default.
- W2539128838 hasConceptScore W2539128838C509974204 @default.
- W2539128838 hasConceptScore W2539128838C55493867 @default.
- W2539128838 hasConceptScore W2539128838C71924100 @default.
- W2539128838 hasConceptScore W2539128838C86803240 @default.
- W2539128838 hasIssue "11" @default.
- W2539128838 hasLocation W25391288381 @default.
- W2539128838 hasOpenAccess W2539128838 @default.
- W2539128838 hasPrimaryLocation W25391288381 @default.
- W2539128838 hasRelatedWork W1982962683 @default.
- W2539128838 hasRelatedWork W2019694656 @default.
- W2539128838 hasRelatedWork W2040074407 @default.
- W2539128838 hasRelatedWork W2079852658 @default.
- W2539128838 hasRelatedWork W2405509401 @default.
- W2539128838 hasRelatedWork W2414079943 @default.
- W2539128838 hasRelatedWork W2417555288 @default.
- W2539128838 hasRelatedWork W2419414806 @default.
- W2539128838 hasRelatedWork W4290436003 @default.
- W2539128838 hasRelatedWork W2610487130 @default.
- W2539128838 hasVolume "108" @default.
- W2539128838 isParatext "false" @default.
- W2539128838 isRetracted "false" @default.
- W2539128838 magId "2539128838" @default.
- W2539128838 workType "article" @default.